The Globe and Mail
Ottawa has temporarily shut down a Southern Ontario pharmaceutical maker to “prevent injury to the health of consumers,” but the federal drug regulator has not recalled any of the inexpensive chemotherapy drug produced at the plant, leading the company to claim it has been unfairly shuttered for minor infractions.
Health Canada suspended the licence of Biolyse Pharma Corp. on April 11, saying in a letter to the St. Catharines-based generic drug maker that an inspection beginning in January “raised significant concerns relating to aseptic manufacturing, chemical testing, microbiological testing controls and documentation.”
Read more about the news here.
No comments:
Post a Comment